Edition:
India

Xencor Inc (XNCR.OQ)

XNCR.OQ on NASDAQ Stock Exchange Global Market

39.93USD
1:30am IST
Change (% chg)

$-0.31 (-0.77%)
Prev Close
$40.24
Open
$40.05
Day's High
$40.22
Day's Low
$39.26
Volume
138,324
Avg. Vol
132,278
52-wk High
$43.29
52-wk Low
$19.00

Chart for

About

Xencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials... (more)

Overall

Beta: 2.15
Market Cap(Mil.): $1,163.30
Shares Outstanding(Mil.): 46.93
Dividend: --
Yield (%): --

Financials

BRIEF-Xencor Reports Q1 Loss Per Share $0.62

* Q1 EARNINGS PER SHARE VIEW $-0.46 -- THOMSON REUTERS I/B/E/S

08 May 2018

BRIEF-Xencor Says Public Offering Of 7.30 Mln Common Shares Priced At $31 Per Share

* XENCOR ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

21 Mar 2018

BRIEF-Xencor Files For Potential Mixed Shelf Offering

* XENCOR INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED- SEC FILING ‍​ Source text: (http://bit.ly/2G8MdV1) Further company coverage:

20 Mar 2018

BRIEF-Xencor Announces Proposed Public Offering Of Common Stock

* XENCOR, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

20 Mar 2018

BRIEF-Xencor Reports Q4 Loss Per Share $0.25

* XENCOR REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

28 Feb 2018

BRIEF-Xencor Doses First Patient In Phase 1 Study Of Xmab®18087,An Antibody For Treatment Of Neuroendocrine Tumors And Gastrointestinal Stromal Tumors

* XENCOR DOSES FIRST PATIENT IN PHASE 1 STUDY OF XMAB®18087 BISPECIFIC TUMOR TARGETING ANTIBODY FOR THE TREATMENT OF NEUROENDOCRINE TUMORS AND GASTROINTESTINAL STROMAL TUMORS

22 Feb 2018

BRIEF-Xencor Inc - Expect Initial Data From Phase 2 Trial Of Xmab®5871 In Systemic Lupus Erythematosus

* XENCOR INC - EXPECT INITIAL DATA FROM PHASE 2 TRIAL OF XMAB®5871 IN SYSTEMIC LUPUS ERYTHEMATOSUS

05 Jan 2018

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $36.30 -0.16
Novartis AG (NOVN.S) CHF75.60 +0.10
Roche Holding Ltd. (ROG.S) CHF216.45 --
Roche Holding Ltd. (RO.S) CHF219.60 -1.20
AstraZeneca plc (AZN.L) 5,255.00 -124.00
GlaxoSmithKline plc (GSK.L) 1,538.40 -11.60
AbbVie Inc (ABBV.N) $95.55 -2.70
Bristol-Myers Squibb Co (BMY.N) $53.94 -0.31
Bristol-Myers Squibb Co (BMYMP.PK) $909.45 --
Amgen, Inc. (AMGN.OQ) $185.99 -0.52

Earnings vs. Estimates